• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Harvard Bioscience Inc.

Philips board backs reappointment of CEO van Houten, CFO Bhattacharya | Personnel Moves – October 29, 2018

October 29, 2018 By Fink Densford

Royal Philips (NYSE:PHG) said today that its board of directors is backing the re-appointment of Frans van Houten as its president and CEO and Abhijit Bhattacharya as chief financial officer and board member. CEO van Houten has been at the head of Philips since 2011, while Bhattacharya joined the company in 2015, Amsterdam-based Philips said. During […]

Filed Under: Business/Financial News, Featured Tagged With: aligntechnology, Bovie Medical Corp., Clearside Biomedical, cromsource, Fisher & Paykel Healthcare, Harvard Bioscience Inc., Philips, Ra Medical, RenovaCare, Sight Sciences

Harvard Bioscience lowers guidance in Q3 earnings

October 26, 2018 By Fink Densford

Shares in Harvard Biosciences (NSDQ:HBIO) fell today after the medtech company met expectations on Wall Street with its third quarter earnings results, but dropped its guidance for the full year. The Holliston, Mass.-based company posted losses of $256,000, or 1¢ per share, on sales of $28.6 million for the three months ended September 30, seeing […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Harvard Bioscience Inc.

HART CEO David Green on the transformative potential for regenerative medicine

September 3, 2014 By Brad Perriello Leave a Comment

YYmeta

Filed Under: News Well, Regenerative Medicine Tagged With: Harvard Apparatus Regenerative Technology (HART), Harvard Bioscience Inc., MassDevice Q&A

Layoffs: Harvard Bioscience cuts 13% of workforce

December 5, 2013 By Arezu Sarvestani Leave a Comment

Layoffs: Harvard Bioscience cuts 13% of workforce

Massachusetts medtech company Harvard Bioscience’s (NSDQ:HBIO) announced today that it plans to cut about 13% of its global workforce, expecting to reap about $2 million in annual savings.

Filed Under: News Well Tagged With: Harvard Bioscience Inc., Layoffs

World’s 1st regenerated trachea recipient faring well at 5 years

October 24, 2013 By Arezu Sarvestani Leave a Comment

World's 1st regenerated trachea recipient faring well at 5 years, Harvard Bioscience says

Filed Under: News Well, Regenerative Medicine, Research & Development Tagged With: Harvard Apparatus Regenerative Technology (HART), Harvard Bioscience Inc., Organ Transplant, Tissue Regeneration

Harvard Bioscience ditches IPO in favor of a spin-out

October 21, 2013 By Arezu Sarvestani Leave a Comment

Harvard Bioscience ditches IPO in favor of a spin-out

Harvard Bioscience’s (NSDQ:HBIO) regenerative therapies business will begin operating as an independent, publicly traded company at the start of next month, ditching original plans to launch an initial public offering.

Filed Under: News Well, Regenerative Medicine, Wall Street Beat Tagged With: Harvard Bioscience Inc.

Insulet appoints 1st medical director | Personnel Moves

October 17, 2013 By Chris Walker Leave a Comment

fired/hired

Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.

Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.

Filed Under: News Well Tagged With: AcuFocus Inc., Exactech Inc., Harvard Apparatus Regenerative Technology (HART), Harvard Bioscience Inc., Hospira Inc., Insulet, Optos Inc., Personnel Moves

Harvard Bio names new CEO amid regenerative therapies spinout

September 25, 2013 By Arezu Sarvestani Leave a Comment

Harvard Bio names new CEO amid organ growing spinout

Massachusetts scientific instrument maker Harvard Bioscience named Jeffrey Duchemin its new CEO, who took over the company in the midst of the spinout of its regenerative therapies unit.

Filed Under: News Well, Regenerative Medicine Tagged With: Harvard Bioscience Inc., Personnel Moves

ConforMIS lures Zimmer ops director to be its new operations SVP | Personnel Moves

May 16, 2013 By Brad Perriello Leave a Comment

ConforMIS lures Zimmer ops director to be its new COO

ConforMIS lured Zimmer’s dental business operations director, Matthew Scott, away to be its new chief operating officer as it looks to scale up its customized knee implant business.

The Bedford, Mass.-based medical device company said Scott bring’s a decade’s worth of ops experience from his tenure at Zimmer. ConforMIS makes knee replacement implants and instrumentation that are custom-fit to patients’ morphology.

Filed Under: Implants, News Well, Orthopedics Tagged With: Cerapedics Inc., conformis, Harvard Bioscience Inc., Knees, Novartis, Orthofix, Personnel Moves, wrightmedical, Zimmer Biomet

Boston Scientific’s Irish ops pulled down $1.4B last year | Wall Street Beat

December 12, 2012 By MassDevice staff Leave a Comment

MassDevice.com Wall Street Beat

Boston Scientific (NYSE:BSX) posted pre-tax profits of $1.4 billion from its Irish unit and other foreign subsidiaries last year, according to the Irish Times.

Marlborough, Mass.-based medical device company Boston Scientific is 1 of the Emerald Isle’s largest employers, with a 4,500-employee workforce there.

Filed Under: Funding Roundup, News Well, Wall Street Beat Tagged With: Bausch + Lomb, BioCision LLC, Boston Scientific, DNA Medicine Institute, Exports, Grove Instruments Inc., Harvard Apparatus Regenerative Technology (HART), Harvard Bioscience Inc., Innovative Trauma Care, sBioMed

First U.S. patient to get stem cell trachea transplant dies

March 6, 2012 By MassDevice staff Leave a Comment

Harvard Bioscience

Christopher Lyles, the 1st U.S. patient and the 2nd worldwide to receive a stem cell trachea transplant, died this month of unknown causes.

Lyles received an experimental trachea grown from his own stem cells and cultivated in a bioreactor made by Harvard Bioscience (NSDQ:HBIO) in November 2011.

Filed Under: News Well, Regenerative Medicine, Stem Cells Tagged With: Harvard Bioscience Inc., Organ Transplant

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS